新規ドラッグデリバリーシステムの世界市場(~2027)

• 英文タイトル:Novel Drug Delivery Systems Market Research Report by Route of Administration, Mode, End-User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Novel Drug Delivery Systems Market Research Report by Route of Administration, Mode, End-User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19「新規ドラッグデリバリーシステムの世界市場(~2027)」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2301G043
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、231ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥742,350 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,492,350 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社は、世界の新規ドラッグデリバリーシステム市場規模が、2021年の7,123.22百万ドルから2022年には7,619.14百万ドルへ増加し、2027年までにCAGR 7.21%拡大して10,820.75百万ドルまで成長すると予測しています。本書では、新規ドラッグデリバリーシステムの世界市場を調査対象とし、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、投与経路別(注射可能ドラッグデリバリーシステム、経口ドラッグデリバリーシステム、肺ドラッグデリバリーシステム、経皮ドラッグデリバリーシステム)分析、モード別(制御ドラッグデリバリーシステム、調節ドラッグデリバリーシステム、標的ドラッグデリバリーシステム)分析、エンドユーザー別(病院、研究センター、専門診療所)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況、企業情報などの内容を整理しました。また、本書に記載されている企業情報にはAbbott Laboratories、AstraZeneca PLC、Bayer AG、Boston Scientific Corporation、Cospheric LLC、EmboMedics, Inc.、Enable Injections, Inc.、F. Hoffmann-La Roche AG、GlaxoSmithKline Plc、Insulet Corporation、Johnson & Johnson、Merck & Co., Inc.、Merit Medical Systems, Inc.、Mo-Sci Corporation、Novartis AG、Pfizer Inc.、Polysciences, Inc.などが含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の新規ドラッグデリバリーシステム市場規模:投与経路別
- 注射可能ドラッグデリバリーシステムの市場規模
- 経口ドラッグデリバリーシステムの市場規模
- 肺ドラッグデリバリーシステムの市場規模
- 経皮ドラッグデリバリーシステムの市場規模
・世界の新規ドラッグデリバリーシステム市場規模:モード別
- 制御ドラッグデリバリーシステムの市場規模
- 調節ドラッグデリバリーシステムの市場規模
- 標的ドラッグデリバリーシステムの市場規模
・世界の新規ドラッグデリバリーシステム市場規模:エンドユーザー別
- 病院における市場規模
- 研究センターにおける市場規模
- 専門診療所における市場規模
・世界の新規ドラッグデリバリーシステム市場規模:地域別
- 南北アメリカの新規ドラッグデリバリーシステム市場規模
アメリカの新規ドラッグデリバリーシステム市場規模
カナダの新規ドラッグデリバリーシステム市場規模
ブラジルの新規ドラッグデリバリーシステム市場規模
...
- アジア太平洋の新規ドラッグデリバリーシステム市場規模
日本の新規ドラッグデリバリーシステム市場規模
中国の新規ドラッグデリバリーシステム市場規模
インドの新規ドラッグデリバリーシステム市場規模
韓国の新規ドラッグデリバリーシステム市場規模
台湾の新規ドラッグデリバリーシステム市場規模
...
- ヨーロッパ/中東/アフリカの新規ドラッグデリバリーシステム市場規模
イギリスの新規ドラッグデリバリーシステム市場規模
ドイツの新規ドラッグデリバリーシステム市場規模
フランスの新規ドラッグデリバリーシステム市場規模
ロシアの新規ドラッグデリバリーシステム市場規模
...
- その他地域の新規ドラッグデリバリーシステム市場規模
・競争状況
・企業情報

The Global Novel Drug Delivery Systems Market size was estimated at USD 7,123.22 million in 2021 and expected to reach USD 7,619.14 million in 2022, and is projected to grow at a CAGR 7.21% to reach USD 10,820.75 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Novel Drug Delivery Systems to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Route of Administration, the market was studied across Injectable Drug Delivery Systems, Oral Drug Delivery Systems, Pulmonary Drug Delivery Systems, and Transdermal Drug Delivery Systems.

Based on Mode, the market was studied across Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, and Targeted Drug Delivery Systems.

Based on End-User, the market was studied across Hospital, Research Centers, and Specialty Clinics.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Novel Drug Delivery Systems market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Novel Drug Delivery Systems Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Novel Drug Delivery Systems Market, including Abbott Laboratories, AstraZeneca PLC, Bayer AG, Boston Scientific Corporation, Cospheric LLC, EmboMedics, Inc., Enable Injections, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Insulet Corporation, Johnson & Johnson, Merck & Co., Inc., Merit Medical Systems, Inc., Mo-Sci Corporation, Novartis AG, Pfizer Inc., Polysciences, Inc., Sanofi SA, Sirtex Medical Inc., Terumo Medical Corporation, and West Pharmaceutical Services, Inc..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Novel Drug Delivery Systems Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Novel Drug Delivery Systems Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Novel Drug Delivery Systems Market?
4. What is the competitive strategic window for opportunities in the Global Novel Drug Delivery Systems Market?
5. What are the technology trends and regulatory frameworks in the Global Novel Drug Delivery Systems Market?
6. What is the market share of the leading vendors in the Global Novel Drug Delivery Systems Market?
7. What modes and strategic moves are considered suitable for entering the Global Novel Drug Delivery Systems Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing presence of geriatric population with increasing requirements for controlled drug release technologies
5.1.1.2. Significant growth in need for advanced therapies by chronically diseased population
5.1.1.3. Increasing consumer preference for self drug administration
5.1.2. Restraints
5.1.2.1. Concerns regarding drug failures and drug delivery system recalls
5.1.3. Opportunities
5.1.3.1. Ongoing advancements for development of novel drug delivery systems
5.1.3.2. Favorable governmental initiatives and investments for home healthcare settings worldwide
5.1.4. Challenges
5.1.4.1. Limited potential as carrier to non-phagocyte target tissue
5.2. Cumulative Impact of COVID-19

6. Novel Drug Delivery Systems Market, by Route of Administration
6.1. Introduction
6.2. Injectable Drug Delivery Systems
6.3. Oral Drug Delivery Systems
6.4. Pulmonary Drug Delivery Systems
6.5. Transdermal Drug Delivery Systems

7. Novel Drug Delivery Systems Market, by Mode
7.1. Introduction
7.2. Controlled Drug Delivery Systems
7.3. Modulated Drug Delivery Systems
7.4. Targeted Drug Delivery Systems

8. Novel Drug Delivery Systems Market, by End-User
8.1. Introduction
8.2. Hospital
8.3. Research Centers
8.4. Specialty Clinics

9. Americas Novel Drug Delivery Systems Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Novel Drug Delivery Systems Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Novel Drug Delivery Systems Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Abbott Laboratories
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AstraZeneca PLC
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Bayer AG
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Boston Scientific Corporation
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Cospheric LLC
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. EmboMedics, Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Enable Injections, Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. F. Hoffmann-La Roche AG
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. GlaxoSmithKline Plc
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Insulet Corporation
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Johnson & Johnson
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Merck & Co., Inc.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Merit Medical Systems, Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Mo-Sci Corporation
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Novartis AG
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Pfizer Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Polysciences, Inc.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Sanofi SA
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Sirtex Medical Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Terumo Medical Corporation
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. West Pharmaceutical Services, Inc.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing




• 英文レポート名:Novel Drug Delivery Systems Market Research Report by Route of Administration, Mode, End-User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
• 日本語訳:新規ドラッグデリバリーシステムの世界市場(~2027)
• レポートコード:MRC2301G043お問い合わせ(見積依頼・ご注文・質問)